Xeris Biopharma (XERS) Stock Price, News & Analysis

Company Overview

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Key Stats

• Today's Range: $7.87 to $8.00
• 50-Day Range: $4.51 to $7.99
• 52-Week Range: $2.48 to $8.02
• Volume: 986,186 shs
• Average Volume: 2.55 million shs
• Market Capitalization: $1.27 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.08
• Consensus Rating: Moderate Buy

Xeris Biopharma Stock Analysis - MarketRank™

Xeris Biopharma scored higher than 68% of companies evaluated by MarketBeat, and ranked 327th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Xeris Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Xeris Biopharma has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Xeris Biopharma are expected to grow in the coming year, from ($0.41) to ($0.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Xeris Biopharma is -37.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Xeris Biopharma is -37.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

12.06% of the float of Xeris Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Xeris Biopharma has a short interest ratio ("days to cover") of 7.4.

Change versus previous month

Short interest in Xeris Biopharma has recently decreased by 6.80%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Xeris Biopharma does not currently pay a dividend.

Dividend Growth

Xeris Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.57

Percentage of Shares Shorted

12.06% of the float of Xeris Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Xeris Biopharma has a short interest ratio ("days to cover") of 7.4.

Change versus previous month

Short interest in Xeris Biopharma has recently decreased by 6.80%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.08

News Sentiment

Xeris Biopharma has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 17 news articles for Xeris Biopharma this week, compared to 3 articles on an average week.

Search Interest

19 people have searched for XERS on MarketBeat in the last 30 days. This is an increase of 19% compared to the previous 30 days.

MarketBeat Follows

10 people have added Xeris Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 900% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Xeris Biopharma insiders have sold 901.19% more of their company's stock than they have bought. Specifically, they have bought $109,500.00 in company stock and sold $1,096,300.00 in company stock.

Percentage Held by Insiders

Only 6.47% of the stock of Xeris Biopharma is held by insiders.

Percentage Held by Institutions

42.75% of the stock of Xeris Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

XERS Stock Analysis - Frequently Asked Questions

How have XERS shares performed this year?

Xeris Biopharma's stock was trading at $3.39 at the start of the year. Since then, XERS stock has increased by 134.1% and is now trading at $7.9350.

How were Xeris Biopharma's earnings last quarter?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) posted its quarterly earnings results on Thursday, August, 7th. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.02. The business earned $67.71 million during the quarter, compared to analysts' expectations of $64.58 million.
Read the conference call transcript.

When did Xeris Biopharma IPO?

Xeris Biopharma (XERS) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Mizuho Securities was co-manager.

Who are Xeris Biopharma's major shareholders?

Top institutional shareholders of Xeris Biopharma include Geode Capital Management LLC (2.33%), Qube Research & Technologies Ltd (1.91%), Rosalind Advisors Inc. (1.33%) and Legal & General Group Plc (1.12%). Insiders that own company stock include Paul R Edick, Kevin Mcculloch, John Patrick Shannon Jr, Beth Hecht, John Johnson and Dawn Halkuff.
View institutional ownership trends.

How do I buy shares of Xeris Biopharma?

Shares of XERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Xeris Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Xeris Biopharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), CymaBay Therapeutics (CBAY) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 8/28/2025
• Next Earnings (Estimated): 11/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:XERS
• CIK: 1867096
• Web: www.xerispharma.com
• Phone: (844) 445-5704
• Fax: N/A
• Employees: 290
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Xeris Biopharma: $7.08
• High Price Target: $10.00
• Low Price Target: $4.00
• Potential Upside/Downside: -10.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$54.84 million
• Net Margins: -13.01%
• Pretax Margin: -14.36%
• Return on Equity: N/A
• Return on Assets: -8.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.95
• Quick Ratio: 1.24

Sales & Book Value

• Annual Sales: $203.07 million
• Price / Sales: 6.31
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.12) per share
• Price / Book: -66.13

Miscellaneous

• Outstanding Shares: 161,480,000
• Free Float: 151,032,000
• Market Cap: $1.28 billion
• Optionable: Optionable
• Beta: 0.65